Shinpoong Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Shinpoong Pharmaceutical makes prescription and over-the-counter medicines supplied to patients and healthcare providers.
Listed on KOSPI, South Korea's main stock exchange, it operates as a mid-sized pharmaceutical company, too large to qualify as a small enterprise under Korean classification but below the largest tier. The company operates through a parent entity supported by six unlisted subsidiaries consolidated into its financial reporting.
Summary is AI-generated and may contain errors · figures from DART filings
Shinpoong Pharmaceutical consolidates six unlisted subsidiaries into its group accounts, a structure common among mid-tier Korean pharmaceutical companies listed on KOSPI.
Shinpoong Pharmaceutical in five facts
What does Shinpoong Pharmaceutical do?
Shinpoong Pharmaceutical makes prescription and over-the-counter medicines supplied to patients and healthcare providers.
Where is Shinpoong Pharmaceutical listed and in which sector?
Shinpoong Pharmaceutical (Korean name: 신풍제약) trades under KRX code 019170 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Shinpoong Pharmaceutical?
Its market capitalisation was US$363.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Shinpoong Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Shinpoong Pharmaceutical reported revenue of US$177.1M, operating profit of US$10.8M and net income of US$6.3M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 6.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Material management matter relevant to investment decisionsSep 15
- [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Shinpoong Pharmaceutical updated its previously filed consolidated results for FY2025: revenue of US$160M (+6.15% year on year), operating profit of US$9.73M (from a loss a year earlier) and net income of US$5.73M (from a loss a year earlier).
Earnings · Mar 10 · 2 versions - [Amended] Decision to acquire shares/equity in another company
Shinpoong Pharmaceutical updated the disclosed terms of an acquisition of Hyundai Pharmaceutical, now worth US$20.6M.
M&A · Feb 27 · 2 versions - Treasury share disposal: results reportTreasury Shares · Feb 27
- Material event report (treasury share disposal)
Shinpoong Pharmaceutical disclosed a plan to sell treasury shares worth US$20.7M, about 6.0% of its market value.
Treasury Shares · Feb 26 - Supply contract terminatedSupply contract · Jan 14